Inhibitors of stearoyl-CoA desaturase
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
1. A compound of formula (I):
wherein:
R 1 and R 5 , independently of each other, are hydrogen, unsubstituted lower alkyl, halogen, trifluoromethyl, hydroxy, aryl, alkoxy or NO 2 ;
R1 and R2, optionally, together with the carbon atoms to which they are attached, form a 9-membered ring having 1 or 2 heteroatoms;
R 2 and R 4 , independently of each other, are hydrogen, unsubstituted lower alkyl, lower alkyenyl, alkoxy, halogen, cyano, trifluoromethyl, O-trifluoromethyl or NO 2 ; and
R 3 is hydrogen, unsubstituted lower alkyl, alkoxy or halogen;
wherein at least one of R 1 , R 2 , R 3 , R 4 or R 5 is hydrogen,
and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 , wherein R 1 is halogen, R 4 is alkoxy and R 5 is hydroxy.
3. The compound according to claim 1 , wherein R 1 , R 4 and R 5 are each hydrogen.
4. The compound according to claim 1 , wherein R 2 is halogen, R 4 is halogen and R 5 is hydroxy.
5. The compound according to claim 1 , wherein both R 2 and R 3 are unsubstituted lower alkyl.
6. The compound according to claim 1 , wherein both R 2 and R 5 are trifluoromethyl.
7. The compound according to claim 1 , wherein both R 3 and R 4 are halogen.
8. The compound according to claim 1 , wherein both R 4 and R 5 are halogen.
9. The compound according to claim 1 , wherein R 2 is halogen and R 3 is hydroxy.
10. The compound according to claim 1 , wherein R 2 is halogen and R 5 is NO 2 .
11. The compound according to claim 1 , wherein R 2 is —O-trifluoromethyl and R 5 is hydroxy.
12. The compound according to claim 1 , wherein R 3 is halogen.
13. The compound according to claim 1 , wherein R 4 is unsubstituted lower alkyl.
14. The compound according to claim 1 , wherein R 5 is unsubstituted lower alkyl.
15. The compound according to claim 1 , wherein R 5 is trifluoromethyl.
16. The compound according to claim 1 , wherein R 5 is halogen.
17. The compound according to claim 1 , wherein R 5 is NO 2 .
18. The compound according to claim 1 , wherein said compound is:
6-[4-(3-Bromo-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(5-Bromo-2-hydroxy-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(3-Chloro-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(5-Chloro-2-nitro-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(2,3-Dichloro-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(3,5-Dichloro-2-hydroxy-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(2,6-Dimethyl-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(2-Hydroxy-5-trifluoromethoxy-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one;
6-[4-(2-Nitro-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one; or
6-[4-(2-Trifluoromethyl-benzyl)-piperazin-1-yl]-3H-pyrimidin-4-one.
19. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.